Allare Allari

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Retrieved on: 
Wednesday, June 28, 2023
Exercise, Computershare, Certificate of incorporation, Therapy, CUSIP, Allare Allari, Security (finance)

The CUSIP number for Allarity’s common stock following the reverse stock split will be 016744302.

Key Points: 
  • The CUSIP number for Allarity’s common stock following the reverse stock split will be 016744302.
  • As a result of the reverse stock split, at the Effective Time, every 40 shares of Allarity’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share.
  • The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Allarity’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.
  • The reverse stock split will reduce the number of shares of Allarity’s common stock outstanding from 20,142,633 shares to approximately 503,565 shares.

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

Retrieved on: 
Tuesday, June 27, 2023
Certificate of incorporation, Therapy, Allare Allari

BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is issuing this press release to clarify the effective date of its contemplated reverse stock split.

Key Points: 
  • BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is issuing this press release to clarify the effective date of its contemplated reverse stock split.
  • The Company is clarifying that the reverse stock split will not be effected on June 27, 2023, and will continue to trade without giving effect to the proposed reverse stock split until further notice.
  • The effective date and time of the actual reverse stock split will be subsequently announced in a separate press release.
  • The reverse stock split is primarily intended to increase the Company’s per share trading price and bring the Company into compliance with Nasdaq’s listing requirement regarding minimum share price, as well as to support the Company’s efforts to raise additional capital.

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

Retrieved on: 
Thursday, December 1, 2022
Ovarian cancer, Cisplatin, COVID-19, Annual, Glioblastoma, RNA, Therapy, Cancer, Ixabepilone, Trial of the century, Clinical trial, Doxorubicin, Literature, Allare Allari, NDA, GBM, Security (finance), Patient, Partnership, PARP, Risk, PMA, Pharmaceutical industry

Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.

Key Points: 
  • Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.
  • The annual meeting was rescheduled to January 19, 2023 in light of the new proposals to be considered at the annual meeting.
  • Stockholders of record as of December 6, 2022, will be entitled to notice of, and to vote at, the 2023 ASM.
  • The Company, however, reserves the right to change the record date prior to the 2023 ASM.

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

Retrieved on: 
Tuesday, October 11, 2022
Finance, Therapy, Administration, Ixabepilone, D, Intangible asset, University, R, CEO, Cancer, GBM, LLC, Research and development, Senior, Private Securities Litigation Reform Act, Jacobs School of Medicine and Biomedical Sciences, Company, Department, Osteosarcoma, Clinical trial, Literature, FDA, Society for Integrative Oncology, G&A, Risk, Division, Security (finance), Trial of the century, Board, Dean (education), CPA, U.S. Securities and Exchange Commission, Wolf, Ovarian cancer, Compliance, University at Buffalo, PARP, Department of Medicine – University of Pamplona, Patient, Biotechnology, Doxorubicin, Professor, RNA, Partnership, Nasdaq, Biomedical sciences, Research, Cisplatin, Forward-looking statement, COVID-19, Glioblastoma, Pharmaceutical industry, Online gambling, Management, Medicine, Allare Allari

On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.

Key Points: 
  • On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.
  • With this filing, the Company has addressed the cause of the non-compliant status with Nasdaq Listing Rule 5250(c)(1), as previously announced on August 26, 2022 .
  • On October 10, 2022, Nasdaq provided confirmation that upon the filing of the Companys Form 10-Q has regained compliance with Nasdaq Listing Rule 5250(c)(1) and the matter is now closed.
  • "We are very pleased to have completed the necessary Q2 filings and to have regained compliance with Nasdaqs listing requirements, said James G. Cullem, Chief Executive Officer at Allarity.

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

Retrieved on: 
Monday, September 26, 2022
Allare Allari, Therapy, Trial of the century, COVID-19, Director, Risk, Glioblastoma, Literature, LLC, Villanova University, Ovarian cancer, Company, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Ixabepilone, Forward-looking statement, Patient, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, CEO, MBA, Nasdaq, Board of directors, Neos, PARP, Drug development, Board, RNA, Merck & Co., Biotechnology, Security (finance), Merck, Pharmaceutical industry

Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management.

Key Points: 
  • Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management.
  • I am delighted that Jerry has chosen to join Allaritys board at this crucial time in our evolution, said Dr. Duncan Moore, Allaritys Chairman of the Board.
  • Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.)
  • Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc.

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Friday, September 16, 2022
Allare Allari, Therapy, Trial of the century, COVID-19, Risk, Glioblastoma, Literature, Ovarian cancer, Company, Compliance, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Track, Ixabepilone, Forward-looking statement, Patient, Clinical trial, File, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, Nasdaq, PARP, Form 10-Q, Form, RNA, Security (finance), Conference, Ladenburg Thalmann, SEC, Webcast, Pharmaceutical industry

Cambridge, MA U.S.A. (September 16, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1x1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY.

Key Points: 
  • Cambridge, MA U.S.A. (September 16, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1x1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY.
  • Investors interested in meeting with Allarity Therapeutics should contact their Ladenburg Thalmann representative or email the Company at [email protected].
  • In addition, the webcast will be available on the investor section of the Allarity website, and will be archived for 30 days following the conference.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Announces Appointment of New Auditor

Retrieved on: 
Monday, September 12, 2022
Therapy, Trial of the century, COVID-19, Wolf, Director, Risk, Glioblastoma, Literature, Ovarian cancer, Company, Compliance, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Ixabepilone, Forward-looking statement, Patient, Clinical trial, File, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, P.C, Compte rendu, PARP, Form 10-Q, Board, Form, RNA, Security (finance), SEC, Pharmaceutical industry, Allare Allari, Nasdaq

Cambridge, MA U.S.A. (September 12, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C.

Key Points: 
  • Cambridge, MA U.S.A. (September 12, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C.
  • The appointment of Wolf & Company has been approved by both the audit committee and the Board of Directors (the Board) of the Company.
  • The appointment of Wolf & Company has no immediate effect on the Companys status as being non-compliant with Nasdaq Listing Rule 5250(c)(1).
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Retrieved on: 
Friday, August 26, 2022
Literature, Partnership, Security (finance), COVID-19, U.S. Securities and Exchange Commission, Allare Allari, RNA, Cancer, GBM, Therapy, File, Calendar, Doxorubicin, Letter, Forward-looking statement, SEC, Cisplatin, PARP, Form 10-Q, Company, Compliance, Glioblastoma, Ixabepilone, Form, Risk, Clinical trial, Ovarian cancer, Private Securities Litigation Reform Act, Trial of the century, Patient, Pharmaceutical industry, Nasdaq

This notification has no immediate effect on the listing of the Companys common stock on the Nasdaq.

Key Points: 
  • This notification has no immediate effect on the listing of the Companys common stock on the Nasdaq.
  • However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Companys common stock will be subject to delisting from Nasdaq.
  • Under the Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

Retrieved on: 
Tuesday, August 2, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Cisplatin, Time, Doxorubicin, Literature, MRCC, GBM, Type, U.S. Securities and Exchange Commission, Food, Ixabepilone, Trial of the century, Forward-looking statement, Fibroblast growth factor receptor, Partnership, Private Securities Litigation Reform Act, NDA, Risk, Board, Therapy, COVID-19, Coronavirus Scientific Advisory Board (Turkey), Cancer, Clinical trial, FDA, Company, Board of directors, Patient, Interim, Nasdaq, PARP, Security (finance), Â, Glioblastoma, Ovarian cancer, SAB, RNA, Pharmaceutical industry, Allare Allari

Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.

Key Points: 
  • Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.
  • Significantly broaden the Companys possibilities for future commercial partnering with larger pharmaceutical companies to maximize the value of its pipeline assets and DRP platform technology.
  • The Company is currently evaluating other potential Phase 1b/2 studies for either stenoparib or dovitinib combined with another oncology therapeutic, including the mRCC space.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.

Retrieved on: 
Monday, July 11, 2022
Private Securities Litigation Reform Act, Literature, CDK, Pfizer, Breast cancer, Therapy, PARP, Ixabepilone, Partnership, Harvard Medical School, NDA, CMO, GBM, Senior, New England, Doxorubicin, Patient, Clinical trial, Trial of the century, Beth Israel Deaconess Medical Center, Assistant, Audit committee, Massachusetts Institute of Technology, Division, Company, Forward-looking statement, Nasdaq, U.S. Securities and Exchange Commission, ER, Security (finance), Ovarian cancer, Drug, Internal medicine, RNA, Cisplatin, PMA, COVID-19, Housing, Communities and Local Government Committee, Industry, Development, Tufts Medical Center, Risk, Technology, Cancer, Board, Glioblastoma, Board of directors, Pharmaceutical industry, Hematology, Allare Allari, Syros

Dr. Roth will bring to Allarity deep experience and expertise in the development and commercialization of oncology therapeutics, including regulatory strategy.

Key Points: 
  • Dr. Roth will bring to Allarity deep experience and expertise in the development and commercialization of oncology therapeutics, including regulatory strategy.
  • Dr. Duncan Moore, Ph.D. will continue to serve as the Boards Chairman and as Chair of the Audit Committee.
  • We look forward to his insights as we continue to refine our clinical strategy.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.